Breaking News, Collaborations & Alliances

Catalent Enters COVID-19 Vax Pact with Spicona

Will leverage GPEx cell line development platform to develop COVID-19 vaccine

By: Contract Pharma

Contract Pharma Staff

Catalent has signed an agreement with Spicona to develop a virus-like protein (VLP)-based vaccine against COVID-19. Catalent will use its proprietary GPEx cell line development technology to develop a cell line expressing the recombinant VLP at its Madison, WI facility.   Spicona is focused on research and development in the field of immunology and vaccinology. Its pipeline is being built around novel compounds for the prevention and treatment of infectious diseases, with an immediate focus on t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters